InterveXion has been awarded a two year $3.9 million grant entitled “Chimeric anti-Methamphetamine Monoclonal Antibody for Treating Stimulant Toxicity” by the National Institutes of Health, National Institute on Drug Abuse (NIDA) as part of the American Recovery and Reinvestment Act of 2009. W. Brooks Gentry, M.D. and R. Barry Holtz, Ph.D. are the principal investigators. Their application was selected from a highly competitive pool and awards were given to institutions and companies that could show that the funds would accelerate programs toward a major milestone or commercialization endpoint. The funds will be used to move the methamphetamine mAb product toward the clinic by developing the large-scale manufacturing process, conducting IND-enabling toxicology testing, and completing the clinical preparations. By the end of the funding period, InterveXion will be ready for a Phase I clinical trial.
- InterveXion Therapeutics Announces Fast Track Designation of IXT-m200 for Treatment of Methamphetamine Addiction
- InterveXion Therapeutics, a UAMS Startup, Receives $14.5 Million to Develop Drug Therapies for Methamphetamine Users
- InterveXion publishes results of Phase 1a study of ch-mAb7F9
- Anti-METH Antibody Shortens the Time Rats are Affected by Repeated Doses of METH
- Two Anti-METH Antibodies Reduce METH-Induced Locomotor Effects and Favorably Alter METH Kinetics in Rats